The Newport Phase III Drugs Module extends the coverage of APIs from approved and/or launched drugs to include more than 400 compounds in late stage development (Phase III clinical, registration or under review).
In today’s hyper-competitive generics industry, sophisticated and aggressive generic companies and API manufacturers looking to gain a competitive edge need the ability to target new opportunities for development at the earliest possible opportunity.
Using this add-on module, customers can view patent, synthesis and clinical development details for late-stage compounds and begin their targeting and competitive tracking processes earlier than ever before.
The Newport Phase III Drugs Module is an optional subscription module that may be added to Newport Premium (for Generics) or Newport Global (for Generics) product configurations. A subscription to either Premium or Global base system is required before purchasing this module.
With Newport Phase III Drugs Module, you can:
- Start product targeting earlier
- Anticipate line-extensions for products in the market and innovators’ strategies for protecting their franchises
Why choose Newport Phase III Drugs Module?
- Monitor competition
- Improve product targeting
- Seek out partners earlier
- For products still in phase III clinical development and in pre-registration or registration: originator, licensee, patents, chemical structure, routes of synthesis, development status by country and therapy area
- For all products in phase III and above: Clinical trial status changes by country, therapy area, and company developing the molecule.
- Ability to include or exclude phase III molecules from already powerful targeting searches.
Contact Us
Thomson Reuters
API Intelligence
215 Commercial Street
Portland, Maine 04101
Tel: +1 207.871.9700
Fax: +1 207.871.9800